The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for the novel drug is intended for use in ALS but it may be beneficial in renal dialysis patients as well as for Covid19 infections. TVALA® is the first molecule being developed by NDR. The potential ALS treatment was designed in a program to develop non-hydrolyzing analogs of anti-inflammatory peptides. TVALA® is scheduled for FDA review and into clinical trial less than 24 months after its conception in the laboratory. If successful, NDR may lead the way in shortening the pipeline of treatments to ALS patients by keeping the drug in the not-for-profit space.
top of page
Recent Posts
See AllIndiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis (ALS) pa
11
The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R Borchelt (Department of Neuroscience, University of Florida, Colle
11
NDR congratulates Dr. Chandler Walker, Associate Professor in the department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, on the acceptance of his paper repor
7
bottom of page